X4 Pharmaceuticals, Inc.

NASDAQ:XFOR

Biotechnology

Healthcare
$2.98 +1.49%

+$0.06 today

Market cap
$304.30M
Beta
0.37
P/E (TTM)
-5.2
EPS (TTM)
-$0.79
52W Low $1.35High $4.83

Volume 0.64M

Average 0.40M

XFOR Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

X4 Pharmaceuticals, Inc.NASDAQ: XFOR

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit declines year over year

Q1 FY2026 gross profit of $2.11M fell 91.1% year over year, behind the -71.7% change in trailing-twelve-month gross profit. Sequentially, it fell 3.3% from the prior quarter.

Context

  • Gross profit amounted to 82.2% of revenue in FY2025, up 13.3 pp from a year earlier.
  • Gross profit increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -91.1% toward the trailing-twelve-month pace of -71.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.11M-3.3% QoQ
Last fiscal yearDec 2025
$28.86M+1539.5% YoY
LTMMar 2026
$7.16M-71.7% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-91.1%——
1 year+1539.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
28.86M USD
Year-over-year change
+1539.5%

Gross Profit vs competitors

How XFOR compares with its peers on the latest reported figures

  • XFOR's LTM Mar 2026 gross profit of $7.16M is the 2nd highest of the 4 companies compared; the peer median is -$108K.
  • Its year-over-year change of -71.7% is the 2nd highest of 4, against a peer median of -316.0%.
  • Gross profit amounts to 79.4% of revenue for XFOR, versus a peer median of 96.0%.
XFOR Competitors Peer median
Gross Profit for XFOR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KPTIKaryopharm Therapeutics Inc.LTM Mar 2026$145.11M +6.2%-2.6%96.0%
XFORX4 Pharmaceuticals, Inc.LTM Mar 2026$7.16M -71.7%—79.4%
INMBINmune Bio, Inc.LTM Mar 2026-$108K -316.0%-48.9%—
OKUROnKure Therapeutics, Inc.LTM Mar 2026-$203K -1591.7%——
Peer median (excluding XFOR) -$108K-316.0%-25.8%96.0%

Competitors are the stored peer set for XFOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0002.56M35.11M
Cost of Revenue1.89M00797K6.26M
Gross Profit(1.89M)001.76M28.86M
Gross Margin———68.8%82.2%
Research & Development48.76M61.06M72.02M81.64M72.22M
Selling, General & Admin24.7M27.02M35.51M61.52M43.52M
Operating Expenses73.46M87.57M107.52M38.16M115.74M
Depreciation & Amortization1.89M513K419K796K1.28M
EBITDA(83.15M)(89.33M)(94.89M)(27.58M)(69.01M)
EBITDA Margin———-1078.5%-196.5%
Operating Income(75.35M)(87.57M)(107.52M)(36.4M)(86.88M)
Operating Margin———-1423.6%-247.4%
Interest Income10K219K4.58M5.77M4.58M
Interest Expense3.64M3.99M5.78M8.77M8.88M
Other Income / Expenses(13.33M)(6.27M)6.43M(739K)7.73M
Income Before Tax(88.68M)(93.84M)(101.09M)(37.14M)(79.16M)
Pre-Tax Margin———-1452.5%-225.4%
Income Tax Expense17K28K78K310K41K
Net Income(88.7M)(93.87M)(101.17M)(37.45M)(79.2M)
Net Margin———-1464.6%-225.6%
EPS (Basic)(119.58)(45.60)(17.07)(5.59)(1.87)
EPS (Diluted)(119.58)(45.60)(17.07)(5.59)(1.87)
Weighted Avg Shares858.3K2.12M5.93M6.7M42.29M
Weighted Avg Shares (Diluted)858.3K2.12M5.93M6.7M42.29M

X4 Pharmaceuticals, Inc.

NASDAQ:XFOR

Intrinsic Alpha fair value

Locked

Current Price

$2.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.